Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3

被引:10
|
作者
Noyes, WR
Rodriguez, R
Knechtle, SJ
Pirsch, JD
Sollinger, HW
DAlessandro, AM
Chappell, R
Belzer, FO
Kinsella, TJ
机构
[1] UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792
[2] UNIV WISCONSIN,SCH MED,DEPT SURG,MADISON,WI 53792
[3] UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53792
关键词
renal transplant rejection; steroids and OKT3; radiation therapy;
D O I
10.1016/0360-3016(95)02159-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the response rate and kidney graft survival following local irradiation to the transplanted renal graft undergoing persistent rejection after medical management including pulse steroids and OKT3. The role of radiation for renal transplant rejection after failure of OKT3 has not been previously reported. Methods and Materials: From July 1, 1988 to July 1, 1994, 72 consecutive patients with kidney graft rejection were treated with local irradiation to the transplanted renal graft following failure of medical management. All patients received pulse steroids and OKT3, an anti-CD3 immunosuppressant. Patients who failed to respond to methylprednisolone and OKT3 therapy were referred for radiation therapy. The median time from the diagnosis of rejection to irradiation was 8 days. All kidney grafts received local graft irradiation to a total of 8 Gy delivered in four daily fractions. Results: Sixty (83%) patients initially responded to radiotherapy at 7 days after completion of radiotherapy, as defined by a decrease in serum creatinine. Thirty-five responding patients have not experienced a second episode of graft rejection. Overall, 43 (60%) patients have renal graft survival, with a median follow-up of 16 months (range of 6-73 months). Conclusion: It is concluded that there is a subgroup of kidney graft patients undergoing graft rejection who are refractory to pulse steroids and OKT3 therapy where irradiation may be an effective modality with high rates of response and a moderate rate of graft survival. However, a prospective, randomized trial in these medically refractory patients is needed to ascertain whether these results are clinically significant.
引用
收藏
页码:1055 / 1059
页数:5
相关论文
共 50 条
  • [21] Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection
    Kamath, S
    Dean, D
    Peddi, VR
    Schroeder, TJ
    Alexander, JW
    Cavallo, T
    First, MR
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1178 - 1180
  • [22] Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection
    Kamath, S
    Dean, D
    Peddi, VR
    Schroeder, TJ
    Alexander, JW
    Cavallo, T
    First, MR
    TRANSPLANTATION, 1997, 64 (10) : 1428 - 1432
  • [23] OKT3 escalating dose regimens provide effective therapy for renal allograft rejection
    Woodle, ES
    Bruce, DS
    Josephson, M
    Cronin, D
    Newell, KA
    Millis, JM
    Piper, JB
    OLaughlin, R
    Thistlethwaite, JR
    CLINICAL TRANSPLANTATION, 1996, 10 (04) : 389 - 395
  • [24] EFFICACY OF OKT3 RETREATMENT FOR REFRACTORY CARDIAC ALLOGRAFT-REJECTION
    OCONNELL, JB
    RENLUND, DG
    GAY, WA
    DEWITT, CW
    HAMMOND, EH
    YOWELL, RL
    JONES, KW
    KARWANDE, SV
    DOTY, DB
    BRISTOW, MR
    TRANSPLANTATION, 1989, 47 (05) : 788 - 792
  • [25] EFFECT OF OKT3 ANTIBODY THERAPY ON CYTOMEGALOVIRUS REACTIVATION IN RENAL-TRANSPLANT RECIPIENTS
    CHOU, S
    NORMAN, DJ
    TRANSPLANTATION PROCEEDINGS, 1985, 17 (06) : 2755 - 2756
  • [26] OKT3 INDUCTION IN PEDIATRIC RENAL-TRANSPLANT RECIPIENTS
    BARTOSH, SM
    THISTLETHWAITE, RJ
    ARONSON, AJ
    CLINICAL RESEARCH, 1992, 40 (02): : A388 - A388
  • [27] Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients
    Peddi, VR
    Kamath, S
    Schroeder, TJ
    Munda, R
    First, MR
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (02) : 285 - 287
  • [28] OKT3 RESCUE THERAPY IN PANCREAS-ALLOGRAFT REJECTION
    STRATTA, RJ
    SOLLINGER, HW
    DALESSANDRO, AM
    PIRSCH, JD
    KALAYOGLU, M
    BELZER, FO
    DIABETES, 1989, 38 : 74 - 78
  • [29] Efficacy of rejection prophylaxis with OKT3
    Abramowicz, D
    Goldman, M
    TRANSPLANTATION, 1996, 62 (05) : 700 - 701
  • [30] THE USE OF OKT3 IN CADAVERIC RENAL-TRANSPLANTATION FOR REJECTION THAT IS UNRESPONSIVE TO CONVENTIONAL ANTI-REJECTION THERAPY
    NORMAN, DJ
    BARRY, JM
    BENNETT, WM
    LEONE, M
    HENELL, K
    FUNNELL, B
    HUBERT, B
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1988, 11 (02) : 90 - 93